These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1193 related articles for article (PubMed ID: 29858752)
1. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752 [TBL] [Abstract][Full Text] [Related]
2. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients. Arias-Pulido H; Cimino-Mathews AM; Chaher N; Qualls CR; Joste N; Colpaert C; Marotti JD; Chamberlin MD; Foisey MG; Prossnitz ER; Emens LA; Fiering S Breast Cancer Res Treat; 2021 Dec; 190(3):477-489. PubMed ID: 34542773 [TBL] [Abstract][Full Text] [Related]
3. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer. Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869 [TBL] [Abstract][Full Text] [Related]
4. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168 [TBL] [Abstract][Full Text] [Related]
5. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104 [TBL] [Abstract][Full Text] [Related]
6. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323 [TBL] [Abstract][Full Text] [Related]
7. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186 [TBL] [Abstract][Full Text] [Related]
8. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. AiErken N; Shi HJ; Zhou Y; Shao N; Zhang J; Shi Y; Yuan ZY; Lin Y Int J Biol Sci; 2017; 13(9):1172-1179. PubMed ID: 29104508 [TBL] [Abstract][Full Text] [Related]
9. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569 [No Abstract] [Full Text] [Related]
10. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Zhang L; Wang XI; Ding J; Sun Q; Zhang S Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176 [TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968 [TBL] [Abstract][Full Text] [Related]
12. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy. Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236 [TBL] [Abstract][Full Text] [Related]
13. Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC). Gong Y; Nagarathinam R; Arisi MF; Gerratana L; Winn JS; Slifker M; Pei J; Cai KQ; Hasse Z; Obeid E; Noriega J; Sebastiano C; Ross E; Alpaugh K; Cristofanilli M; Fernandez SV Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445631 [TBL] [Abstract][Full Text] [Related]
14. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062 [TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578 [TBL] [Abstract][Full Text] [Related]
16. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781 [TBL] [Abstract][Full Text] [Related]
17. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847 [TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy. Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815 [TBL] [Abstract][Full Text] [Related]